Ведение больного с обострением ХОБЛ. Взгляд терапевта

1. Seemungal TAR, Donaldson GC, Paul EA et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1418–22.
2. Connors AFJr, Dawson NV, Tomas C et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment). Am J Respir Crit Care Med 1996; 154: 959–67.
3. Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. The relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847–52.
4. Шмелева Н.М., Сидорова В.П., Белевский А.С., Шмелев Е.И. Пульмонология. 2008; 6.
5. Страчунский Л.С. Практическое руководство по антиинфекционной химиотерапии. М., 2007.
6.Синопальников А.И., Романовских А.Г. Инфекционное обострение хронической обструктивной болезни легких. Cons. Med. 2006; 6 (1).
7. Anthonisen NR, Manfreda J, Warren CP et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: (196–204).
8. Saint S, Bent S, Vittinghof E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analisis. JAMA 1995; 273; 957–60.
9. Ram F, Rodriguez-Roisin R, Granados-Navarrete A et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; 3.
10. Puhan M, Vollenweider D, Latshang T et al. Exacerbations of chronic obstructive pulmonary disease: when are antibiotics indicated? A systematic review. Respir Res 2007; 8: 30.
11. Stockley RA, O'Brien C, Pye A et al. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000; 117: 1638–45.
12. Colour of sputum is a marker for bacterial colonisation in chronic obstructive pulmonary disease Miravitlles et al. Respiratory Research 2010; 11 (58).
13. Siempos I, Dimopoulos G, Korbila I et al. Macrolides, quinolones and amoxicillin/clavulanate for chronic bronchitis: a meta-analysis. Eur Respir J 2007; 29: 1127–37, 23–5.
14. Martinez FJ, Grossman RF, Zadeikis N et al. Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750 mg. Eur Respir J 2005; 25: 1001–10.
15. Starakis I, Gogos CA, Bassaris H. Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis. Int J Antimicrob Agents 2004; 23: 129–37.
16. Schaberg T, Ballin I, Huchon G et al. A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with co–amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis. J Int Med Res 2001; 29: 314–28.
17. File T, Schlemmer B, Garau J et al. Gemifloxacin versus amoxicillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis. The Clinical Study group. J Chemother 2000; 12: 314–25.
18. Dooley KE, Golub J, Goes FS et al. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis 2002; 34: 1607–12.
19. Celli BR, MacNee W et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932–46.
20. Козлов Р.С. и др. ПеГАС 1999–2009, КМАХ. 2010; 12 (4): 329–41.
21. Pechere JC. Modeling and predicting clinical оutcomes of antibiotic therapy. Infect Med 1998; 15 (Suppl. E): 46–5022.
22. Wilson RL, Allegra Huchon G et al. Short and long outcomes of moxifloxacin (MXF) compared to standard antibiotic treatment (STD) in acute exacerbations of chronic bronchitis (AECB). The MOSAIC study. Eur Resp J 2003;  22 (Suppl. 45): 3559A.
23. Дворецкий Л.И., Дубровская Н.В., Грудинина С.А. и др. Клинико-микробиологический мониторинг больных с обострением хронического бронхита, леченных антибактериальными препаратами. Тер. архив. 2006; 3: 25–35.
24. Anzueto A, Rizzo J, Grossman R. The infection-free interval: its use in evaluating antimicrobial treatment of acute exacerbations of chronic bronchitis. Clin Infect Dis 1999; 28: 1344–5.
25. Chodosh S. Clinical significance of the infection-free interval in the management of acute bacterial exacerbations of chronic bronchitis. Chest 2005; 127: 2231–6.
26. White AJ, Gompertz S, Bayley DL et al. Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax 2003; 58: 680–5.
27. Chang KC, Leung CC. Meta-analysis may not be practicable for guiding antibiotic therapy. Eur Respir J 2008; 31: 906–7.
28.Wistrom J, Norrby SR, Myhre EB. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. J Antimicrob Chemother 2001: 47 (1): 43–50.
29. Bont J, Hak E, Birkhoff CE et al. Is co-morbidity taken into account in the antibiotic management of elderly patients with acute bronchitis and COPD exacerbations? Family Practice 2007; p. 1–6.
30. Pal D, Mitra AK. MDR-and CYP3A4-mediated drug-drug interactions. J Neuroimmune Pharmacol 2006; 1 (3): 323–39.
31. Белоусов Ю.Б. Лекарственные поражения печени, ассоциируемые с макролидами. Очевидна ли связь? РМЖ. 2011; 18: 1118.
32. Russo V, Puzio G, Siniscalchi N. Azithromycin-induced QT prolongation in elderly patient. Acta Biomed 2006; 77 (1): 30–2.
33. Paran Y, Mashav N, Henis O et al. Drug-induced torsades de pointes in patients aged 80 years or more. Anadolu Kardiyol Derg 2008; 8 (4): 260–5.
34. Синопальников А.И, Гучев И.А. Макролиды: современные концепции применения. РМЖ. 2004; 3 (3).
35. WHO Model Prescribing Information, Drugs used in bacterial infections. WHO, Geneva, Switzerland 2001.
36. Neu HC, Wilson AP, GrunebergRN. Amoxycillin/clavulanic acid: a review of its efficacy in over 38,500 patients from 1979 to 1992. J Chemother 1993; 5: 67–93.
37. Garau J, Twynholm M, Garcia-Mendez E et al. Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults. J Antimicrob Chemother 2003; 52: 826–36.
38. Henry DC, Riffer E, Sokol WN et al. Randomized double-blind study comparing 3- and 6-day regimens of azithromycin with a 10-day amoxicillin-clavulanate regimen for treatment of acute bacterial sinusitis. Antimicrob Agents Chemother 2003; 47: 2770–4.
39. File TM, Jr, Lode H et al. Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults. Antimicrob Agents Chemother 2004; 48: 3323–31.
40. Sourgens H, Steinbrede H, Verschoor JS et al. Bioequivalence study of a novel Solutab tablet formulation of amoxicillin/clavulanic acid versus the originator filmcoated tablet. Int J Clin Pharmacol Ther 2001; 39: 75–82.
41. Гучев И.А., Козлов Р.С. Безопасность и эффективность различных лекарственных форм амоксициллина/клавулановой кислоты при инфекциях нижних дыхательных путей у взрослых: открытое проспективное рандомизированное исследование. Пульмонология. 2008; 2: 73–80.

Л.И.Дворецкий, Е.В.Сергеева

ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава РФ